Designer Drugs 2017 features 25,114 mass spectra and 19,665 unique compounds predominantly classified as novel psychoactive substances (NPS). The rapid development of these drugs poses serious challenges to current policies, procedures, and methods for detection and identification of these substances. With the dramatic surge of fentanyl addiction, this library helps labs combat the opioid and novel psychoactives epidemics that threaten public health. Designer Drugs 2017 is the largest collection of chemical signatures of NPS and drugs of abuse in the world. The mass spectra found in this impressive mass spectral reference library were compiled by Dr. Peter Roesner and extensively reviewed by the mass spectral experts Giselher Fritschi and Thomas Junge. The Designer Drugs 2017 mass spectral database was developed to support forensics and toxicology labs to combat this global health epidemic. This edition features the addition of over 1,600 new mass spectra and over 800 new, unique compounds in over 30 different classification groups such as, fentanyles, synthetic cannabinoids, and benzodiazepines. With an average quality index per spectrum of 947.8 and 15,949 kovats retention indices this spectral library provides comprehensive data on the most up-to-date list of novel psychoactive substances. New to this edition is additional support for accurate mass workflows, including MassHunter PCD and NIST MS Search (compatible with Thermo, Bruker, JEOL, Leco, PerkinElmer, and others). Updated annually, the 2017 edition covers the range of known novel psychoactive substances through December 31, 2016. Upgrades are available for purchasers of prior editions. Contact your sales person for upgrade information. For compound coverage please refer to www.compoundsearch.com